Enhancing Oncology Model (EOM): Executive Summary and Model Architecture Analysis

ValuesEdge Institutional Analysis | Based on CMS Model Page (Last Modified: July 31, 2026)

---

1. Executive Summary and Strategic Context

What Is This Model and What Problem Does It Solve?

The Enhancing Oncology Model (EOM) is a nationwide voluntary payment model operating under the authority of Section 1115A of the Social Security Act, administered by the CMS Innovation Center (CMMI). The model targets a precisely defined clinical domain: Medicare beneficiaries receiving systemic chemotherapy for seven specific cancer types: high-risk breast cancer, lung cancer, chronic leukemia, small intestine/colorectal cancer, lymphoma, multiple myeloma, and high-risk prostate cancer.

The problem EOM addresses is not abstract. Cancer is a leading cause of mortality in the United States, and existing fee-for-service payment structures have failed to adequately incentivize the coordination, prevention of unnecessary utilization, and end-of-life care quality that cancer patients require. CMS has explicitly identified three failure modes in the current system: unnecessary hospital visits, inadequate end-of-life care, and misalignment toward lower-value cancer therapies. EOM is the agency's structured answer to each of these, embedding financial accountability, required care redesign activities, and quality measurement into a single episode-based framework.

EOM is not a first-generation experiment. It is a refined successor to the Oncology Care Model (OCM), which ran from July 1, 2016 through June 30, 2022. OCM demonstrated that oncology practices could operationalize structural changes — including standardized screening for pain and depression and improved patient communication — under a payment model framework. EOM preserves what worked (including the Monthly Enhanced Oncology Services (MEOS) payment infrastructure) while correcting OCM's design weaknesses: benchmarking was not cancer-type-specific under OCM, financial accountability was insufficiently rigorous, and emerging priorities around social determinants of health and patient-reported outcomes were not yet embedded as requirements.

Strategic Significance for the Value-Based Care Market

EOM's strategic significance operates on several dimensions simultaneously.

First, scope of accountability. EOM holds participating Physician Group Practices (PGPs) financially accountable for total Medicare spending during six-month oncology episodes, including downside risk. This is not shared savings-only participation. Practices that exceed spending thresholds must repay CMS a portion of the excess. This downside structure is a meaningful differentiator from softer value-based arrangements and signals that CMMI is serious about achieving net savings from oncology spend, not merely redistributing administrative burden.

Second, care redesign infrastructure. The MEOS payment — $110 per beneficiary per month for standard beneficiaries and $140 per beneficiary per month for dually eligible individuals — is not a bonus payment for cost reduction. It is a prospective investment in operational capacity: 24/7 clinician access, patient navigation, comprehensive care planning, screening for health-related social needs (HRSNs), and electronic patient-reported outcomes (ePROs). This positions EOM as a care delivery transformation model, not merely a payment experiment. Practices that deploy MEOS payments effectively are building infrastructure applicable well beyond the model's duration.

Third, cancer-type-specific benchmarking. OCM's aggregated benchmarking approach created adverse selection dynamics and blunted performance incentives. EOM's shift to cancer type-specific benchmarks calibrated to historical costs and patient characteristics — including preexisting health conditions — is a technically significant improvement that makes performance attribution more credible and savings calculations more defensible.

Fourth, payer diversification. The participation of BlueCross BlueShield of South Carolina as the model's single commercial payer participant signals that EOM's framework is being tested for commercial applicability. For health systems and oncology practices, this is evidence that the care redesign infrastructure funded by MEOS payments may anchor multi-payer value-based oncology contracts — a critical consideration for practices evaluating return on investment in EOM operational build.

Fifth, performance data transparency. On August 25, 2025, CMS publicly released cost and performance data from the first reconciliation performance period alongside the First Annual Evaluation Report. This is actionable market intelligence for non-participating oncology organizations: it provides the first empirical signals about which cancer types, practice structures, and care delivery approaches are generating savings versus losses under EOM's payment architecture.

A new feature beginning with Performance Period (PP) 6 — the Substance Access Beneficiary Engagement Incentive (BEI) — further extends the model's scope into medication access, applicable to both Cohort 1 (under the Third Amended and Restated Participation Agreement) and Cohort 2 (under the First Amended and Restated Participation Agreement).

Political Context and Administrative Alignment

The Trump administration's CMMI leadership — including Abe Sutton as Deputy Administrator and CMMI Director, Amy Turner as Deputy Director for Policy, and Jacob Schiff as Chief AI and Technology Officer — has maintained EOM as an active model, and the addition of Cohort 2 on July 1, 2025 represents a deliberate expansion decision made under Trump-era CMS leadership. This is notable context: the current administration has signaled interest in CMMI models that demonstrably reduce Medicare expenditures while preserving beneficiary quality, consistent with EOM's dual mandate.

The MIPS payment adjustment exception for MEOS payments — formalized via Federal Register Notice — also reflects administrative continuity in protecting participating practices from regulatory friction that would otherwise undermine the financial attractiveness of EOM participation.

Market Transformation Implications

EOM's current footprint — 23 physician group practices, 1 commercial payer, more than 2,000 practitioners across more than 300 sites of care — is modest relative to the scale of Medicare oncology spend. However, the model's design elements are highly exportable: cancer-type-specific benchmarking, ePRO collection infrastructure, HRSN screening protocols, and the 24/7 access requirement are all increasingly standard expectations in commercial oncology contracting. Oncology practices not participating in EOM that are building relationships with Medicare Advantage plans or commercial payers should treat EOM's design architecture as a de facto template for next-generation oncology value-based contracts.

The model's July 1, 2023 start date for Cohort 1 and July 1, 2025 start date for Cohort 2, with both cohorts running through June 30, 2030, means the oncology VBC market will have substantive EOM performance data available well before the model concludes — creating a competitive intelligence environment where participating practices accumulate operational learning and benchmarking insight that non-participants will not have.

---

2. Model Architecture and Payment Structure

Participation Structure

EOM is structured as a voluntary model open to Physician Group Practices (PGPs). The model currently includes 23 PGPs and 1 commercial payer participant (BlueCross BlueShield of South Carolina), with a collective footprint of more than 2,000 practitioners across more than 300 sites of care.

The model operates in two cohorts:

Cohort	Start Date	End Date	Duration	Governing Agreement
Cohort 1	July 1, 2023	June 30, 2030	7 years	Third Amended and Restated Participation Agreement
Cohort 2	July 1, 2025	June 30, 2030	5 years	First Amended and Restated Participation Agreement

Both cohorts are governed by distinct participation agreements, and both are subject to the Substance Access Beneficiary Engagement Incentive beginning with Performance Period 6.

Participating PGPs are accountable for Medicare beneficiaries who initiate systemic chemotherapy for one of the model's seven eligible cancer types: high-risk breast cancer, lung cancer, chronic leukemia, small intestine/colorectal cancer, lymphoma, multiple myeloma, and high-risk prostate cancer. Episodes are triggered at the point of chemotherapy initiation, not at diagnosis.

PGPs may engage a broader care ecosystem — including specialists, primary care providers, community organizations, social workers, and psychologists — to fulfill whole-person care requirements, but the PGP retains the financial accountability relationship with CMS.

The MIPS payment adjustment exception for MEOS payments has been formally established via Federal Register Notice, meaning that the Merit-based Incentive Payment System payment adjustment factors do not apply to MEOS payments received under EOM. This removes a layer of regulatory risk that would otherwise deter participation from practices managing MIPS performance simultaneously.

Episode Design and Benchmark Construction

An episode of care begins when a Medicare beneficiary receives systemic chemotherapy for one of the seven covered cancer types. Each episode spans six months. Critically, episodes are renewable: beneficiaries whose treatment extends beyond six months may be attributed to multiple consecutive episodes if they continue receiving chemotherapy. This design ensures that EOM captures extended treatment courses — which represent the highest-cost patients — rather than truncating accountability at a single episode.

CMS sets individual spending benchmarks based on two inputs: (1) historical costs and (2) patient characteristics, explicitly including preexisting health conditions. The shift to cancer type-specific benchmarking — a key improvement over OCM — means that each of the seven cancer types has distinct benchmark calculations, preventing cross-subsidization between cancer types with fundamentally different cost profiles (e.g., multiple myeloma versus early-stage breast cancer).

Payment Structures

EOM contains two primary payment mechanisms:

Monthly Enhanced Oncology Services (MEOS) Payments

Beneficiary Category	Monthly MEOS Rate
Standard Medicare beneficiary	$110 per beneficiary per month
Dually eligible individual	$140 per beneficiary per month

MEOS payments are prospective — paid to practices on a monthly basis regardless of episode-level performance outcomes — and are specifically designated to fund the operational infrastructure of care transformation. MEOS payments are not at risk in the performance-based reconciliation and are explicitly excluded from MIPS payment adjustment calculations.

Covered MEOS-funded activities include:

• 24/7 access to a clinician with EHR access
• Patient navigation services
• Comprehensive care planning facilitating shared decision-making
• Screening for health-related social needs (HRSNs)
• Collection and monitoring of electronic patient-reported outcomes (ePROs)

Performance-Based Payment (PBP)

The Performance-Based Payment mechanism governs end-of-episode financial reconciliation. EOM imposes full two-sided risk:

Performance Scenario	Financial Consequence
Total spending below benchmark + quality thresholds met	Participant receives a performance-based payment (savings share)
Total spending exceeds threshold	Participant repays CMS a portion of excess spending

The downside repayment obligation is a defining feature of EOM and represents a more rigorous accountability structure than many CMMI models that offer optional downside risk tracks. All EOM participants are in a downside risk position; there is no upside-only participation track.

Quality performance is not separable from the financial reconciliation: participants must meet quality metrics to access the savings-sharing benefit. Poor quality performance eliminates or reduces performance-based payments even when spending targets are achieved.

Required Care Design Activities (Participant Redesign Activities)

EOM mandates eight core Participant Redesign Activities (PRAs) that all participating PGPs must implement:

#	Required Activity
1	24/7 access to a clinician with EHR access
2	Patient navigation
3	Evidence-based treatment guidelines
4	Comprehensive care plans
5	Screening for social needs (HRSNs)
6	Collection and monitoring of electronic patient-reported outcomes (ePROs)
7	Use of data for continuous quality improvement
8	Use of certified EHR technology

These eight activities collectively represent a minimum operational standard. The MEOS payment is designed to fund these activities, creating a direct link between prospective payment and required infrastructure investment.

Quality Measurement and Data Reporting

Participating practices are required to submit data on quality measures, clinical data, and sociodemographic data. CMS provides regular performance reports to participants covering spending, utilization, and quality performance, along with associated claims data. This creates a continuous feedback loop between CMS analytics and practice operations, supporting the PRA requirement for data-driven quality improvement.

The First Annual Evaluation Report — released publicly on August 25, 2025, alongside cost and performance data from the first reconciliation performance period — provides the model's first formal empirical assessment. Supporting documents include an At-A-Glance report, Executive Summary, and full Appendix, making this the most detailed publicly available signal of early EOM performance dynamics.

Performance Period Timeline

Milestone	Date
Cohort 1 model start	July 1, 2023
Cohort 2 model start	July 1, 2025
First reconciliation performance period data released	August 25, 2025
First Annual Evaluation Report released	August 25, 2025
Substance Access BEI begins	Performance Period 6
Cohort 1 model end	June 30, 2030
Cohort 2 model end	June 30, 2030

Strategic Architecture Takeaways for Executives

For oncology practice executives and physician group administrators: The mandatory downside risk structure and eight required PRAs create a substantial operational commitment. The MEOS payment ($110–$140/beneficiary/month) provides prospective capital, but practices must assess whether current infrastructure — particularly EHR integration, patient navigation staffing, and ePRO collection workflows — can absorb PRA requirements without exceeding MEOS funding.

For CFOs: The two-sided risk structure requires actuarial modeling of episode-level spend by cancer type against CMS's historical benchmarks. The cancer-type-specific benchmarking improvement reduces blended-benchmark cross-subsidization risk, but practices with heavy multiple myeloma or lung cancer patient panels face higher inherent cost volatility.

For health system strategists: The dual-cohort structure through June 30, 2030 means the competitive learning gap between EOM participants and non-participants will widen through the end of the decade. First Annual Evaluation Report data and future performance period releases will become increasingly actionable market intelligence as the model matures.

For Medicare Advantage plan strategists: The participation of BlueCross BlueShield of South Carolina as a payer partner signals commercial applicability of EOM's design framework. The eight PRAs — particularly HRSN screening, ePROs, and 24/7 access — align with MA quality bonus program priorities and may accelerate oncology network contracting expectations in commercial markets.

---

Contact the EOM team at EOM@cms.hhs.gov | CMS Innovation Center listserv available for model updates